Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 1104-1107

  Levin, Mark David ^a   den Hollander, Jan G ^b   van der Holt, Bronno ^b   Rijnders, Bart J ^b   van Vliet, Martin ^b   Sonneveld, Pieter ^b   van Schaik, Ron H N ^b  

^a ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Leukaemia; Liver; Pharmacokinetics; Transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A5; GAMMA GLUTAMYLTRANSFERASE; VORICONAZOLE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; INVASIVE CANDIDIASIS; LIVER TOXICITY; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; RETROSPECTIVE STUDY; SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS, TOXIC; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 35448963089     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm330     Document Type: Article

References (15)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26 781-803.
2. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
3. Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-7.
4. den Hollander JG, van Arkel C, Rijnders BJ et al. Incidence of voriconazole hepatotoxicity during intravenous and oral treatmant for invasive fungal infections. J Antimicrob Chemother 2006; 57: 1248-50.
5. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
6. Lutsar I, Hodges MR, Tomaszewski K et al. Safety of voriconazole and dose individualization. Clin Infect Dis 2003; 36: 1087-8.
7. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab 2003; 31: 540-7.
8. Ikeda Y, Umemura K, Kondo K et al. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 75: 587-8.
9. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002; 35: 1273-5.
10. Burian M, Grösch S, Tegeder I et al. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 2002; 54: 518-21.
11. van Schaik RH, van der Heiden IP, van den Anker JN et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48: 1668-71.
12. Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous - to oral dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53.
13. Geist MJ, Egerer G, Burhenne J et al. Safety of voriconazolle in a patient with CYP2C9*2/CYP2C9*2 genotype. Antimicrob Agents Chemother 2006; 50: 3227-8.
14. Mikus G, Schowel V, Drzewinska M et al. Cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006; 80: 126-35.
15. Lazarus HM, Blumer JL, Yanovich S et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: A dose escalation study. J Clin Pharmacol 2003; 42 393-400.